Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Exchange Rate Effect (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Exchange Rate Effect for 9 consecutive years, with -$656000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Exchange Rate Effect rose 66.32% to -$656000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 300.0% increase, with the full-year FY2025 number at $4.0 million, up 300.0% from a year prior.
  • Exchange Rate Effect was -$656000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $294000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $2.9 million in Q2 2025 to a low of -$1.9 million in Q4 2024.
  • A 5-year average of -$13450.0 and a median of -$264000.0 in 2021 define the central range for Exchange Rate Effect.
  • Peak YoY movement for Exchange Rate Effect: tumbled 421.8% in 2024, then surged 549.69% in 2025.
  • Ultragenyx Pharmaceutical's Exchange Rate Effect stood at -$392000.0 in 2021, then surged by 444.9% to $1.4 million in 2022, then plummeted by 52.59% to $641000.0 in 2023, then plummeted by 403.9% to -$1.9 million in 2024, then surged by 66.32% to -$656000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Exchange Rate Effect are -$656000.0 (Q4 2025), $294000.0 (Q3 2025), and $2.9 million (Q2 2025).